Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBT-006 in Meibomian Gland Dysfunction
NCT04884243Phase 2Completed
- Sponsor
- Cloudbreak Pharma
- Start
- Sep 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CBT-006 in meibomian gland dysfunction (MGD), sponsored by Cloudbreak Pharma. Started Sep 2021; status: completed.
02
Drugs
CBT-006
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT04884243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04884243.